LONDON--(BUSINESS WIRE)--June 8, 2006--Morria Biopharmaceuticals Plc, a biopharmaceutical company focusing on novel, non-steroidal anti-inflammatory drugs, announced today that its leading oral drug candidate, MRX-5, markedly ameliorated IBD symptoms in independently-conducted pre-clinical studies in animals.
